BIO - Bio-Rad Laboratories, Inc.

NYSE - NYSE Delayed Price. Currency in USD
Currency in USD

Valuation measures

Market cap (intra-day) 513.95B
Enterprise value 313.77B
Trailing P/E 9.13
Forward P/E 152.15
PEG Ratio (5 yr expected) 13.79
Price/sales (ttm)5.99
Price/book (mrq)2.25
Enterprise value/revenue 35.91
Enterprise value/EBITDA 634.22

Trading information

Stock price history

Beta (5Y monthly) 1.07
52-week change 352.92%
S&P500 52-week change 35.66%
52-week high 3497.42
52-week low 3307.26
50-day moving average 3460.96
200-day moving average 3406.66

Share statistics

Avg vol (3-month) 3300.37k
Avg vol (10-day) 3200.83k
Shares outstanding 524.57M
Float 21.18M
% held by insiders 114.29%
% held by institutions 179.15%
Shares short (14 Jun 2020) 4449.85k
Short ratio (14 Jun 2020) 41.95
Short % of float (14 Jun 2020) 42.11%
Short % of shares outstanding (14 Jun 2020) 41.52%
Shares short (prior month 14 May 2020) 4496.93k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 22:1
Last split date 307 Mar 2002

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)30 Mar 2020

Profitability

Profit margin 67.80%
Operating margin (ttm)11.49%

Management effectiveness

Return on assets (ttm)2.15%
Return on equity (ttm)28.31%

Income statement

Revenue (ttm)2.33B
Revenue per share (ttm)78.01
Quarterly revenue growth (yoy)3.20%
Gross profit (ttm)1.26B
EBITDA 402.53M
Net income avi to common (ttm)1.58B
Diluted EPS (ttm)52.29
Quarterly earnings growth (yoy)-20.70%

Balance sheet

Total cash (mrq)1.04B
Total cash per share (mrq)34.97
Total debt (mrq)648.4M
Total debt/equity (mrq)10.30
Current ratio (mrq)2.40
Book value per share (mrq)212.27

Cash flow statement

Operating cash flow (ttm)477.76M
Levered free cash flow (ttm)396.33M